FindTrial
Sign In

Predictors of risks due to adriamycin-based treatment in breast cancer.

A prognostic risk model for the occurrence of serious adverse events in breast cancer patients on Adriamycin-based chemotherapy. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/06/069073
Enrollment
688
Registered
2024-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: NIL, as this is an observational study.: NIL, as this is an observational study. Control Intervention1: NIL, as this is an observational study.: NIL, as this is an observational study.

Sponsors

Kasturba Medical College MAHE Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Women above the age of 18 years diagnosed with breast cancer and receiving Adriamycin based therapy.

Exclusion criteria

Exclusion criteria: Women suffering from any other malignancies or on any other anti-cancer drugs.

Design outcomes

Primary

MeasureTime frame
Occurrence of serious adverse events (SAE) in breast cancer patients on adriamycin based regimen.Timepoint: Risk factor data will be collected & assessed following Adriamycin-based regimen every day for 21 days at cycles 1,2,3,4,5 & 6.—

Secondary

MeasureTime frame
To study the pattern of serious adverse events in breast cancer patients on adriamycin-based regimen.Timepoint: Data on SAEs will be collected as per the predetermined data collection tool following Adriamycin-based regimen every day for 21 days at cycles 1,2,3,4,5 & 6.—

Countries

India

Contacts

Public ContactDr R Siddhanth

Kasturba Medical College, MAHE, Manipal

shiva.g@manipal.edu919449553742

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026